Patients are returning in Europe, but China and US lag behind, says Coloplast's CEO

Things are looking better in Europe for Medtech firm Coloplast, as patient numbers are returning to pre-Covid-19 levels. However, challenges remain outside the region, CEO Kristian Villumsen says.

Kristian Villumsen, CEO of Coloplast | Photo: Stine Bidstrup/ERH

Signs of a patient influx recovery for Coloplast’s segment have appeared – particularly in Europe, where the patient numbers are almost the same as prior to the Covid-10 pandemic, says the medtech company’s CEO, Kristian Villumsen, in an interview with MarketWire.

However, he says there are still challenges outside Europe, particularly in the US, where the inflow of new patients in Coloplast’s Continence Care business continues to lag behind, and also in China, where consumer pattern have changed, resulting in reduced sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs